Top 5 Papers
#1
Source: The Lancet Digital Health | Authors: Cold KM, Vamadevan A, Heen A, et al. (CAMES Rigshospitalet + three Danish university hospitals) | Published: September 2, 2026
Score: 12/20 — Base 7 (Lancet Digital Health — Lancet-family specialty title, added to the scoring table this run) + multicentre randomised controlled trial (+3) + clinical impact (+2: primary endpoint met, and adenocarcinoma detection — not just adenomas — improved, with ADR a validated surrogate for CRC incidence and mortality). No colleague-engagement bonus: the X KOL sweep surfaced no qualifying new posts on this paper.
A stepped-wedge cluster-randomised trial across three Danish university hospitals tested computer-aided quality (CAQ) feedback delivered to endoscopists after the procedure — not computer-aided detection during it. Among 2110 FIT-positive patients aged 50–74, with 17 endoscopists acting as their own controls across three clusters, adenoma detection rate rose from 43.4% to 48.6% (OR 1.24, 95% CI 1.02–1.52, p=0.032), and adenocarcinoma detection rate from 6.5% to 8.9% (OR 1.51, 95% CI 1.06–2.15, p=0.027). Polyp detection rate improved marginally (54.2% vs 50.7%, OR 1.22, 95% CI 1.00–1.49, p=0.048) and withdrawal time lengthened from 915 to 960 seconds (IRR 1.11, 95% CI 1.06–1.17, p=0.003). Adenomas per colonoscopy did not reach significance (1.00 vs 0.85, IRR 1.15, 95% CI 0.99–1.33, p=0.069), so the effect is better read as more patients with a lesion found than more lesions per patient. This is a different intervention from the CADe trials this digest has covered — the feedback loop targets the operator, and the gain persisted rather than depending on a device being switched on.
Post angle: Every CADe trial asks the machine to find the polyp. This one made the endoscopist better — and the adenocarcinoma detection rate moved too. #GIOnc #CRC #Colonoscopy
#2
Source: Signal Transduction and Targeted Therapy | Authors: Liu Y, et al.; senior authors Yuan Y, Ding K (multicentre, China) | Published: September 1, 2026
Score: 11/20 — Base 8 (Signal Transduction and Targeted Therapy — Nature-portfolio title added to the scoring table this run; it had been defaulting to Other = 5, which badly understated a 748-patient first-line phase 3) + Phase III RCT (+3) + clinical impact (+0: this is a negative trial — no survival benefit, no new standard of care, no biomarker-guided signal). No colleague-engagement bonus.
ANCHOR randomised 748 patients with RAS/BRAF wild-type metastatic colorectal cancer 1:1 to first-line anlotinib (n=373) or bevacizumab (n=375), each with chemotherapy, at multiple Chinese centres (NCT04854668 / CTR20210940). At a median follow-up of 25.1 months (95% CI 23.8–26.3), median PFS was identical at 11.0 months in both arms, with a stratified HR of 1.00 (95% CI 0.84–1.18, p=0.87). The prespecified noninferiority margin was HR 1.09, and the confidence interval crosses it — so noninferiority was not met, and the trial does not license substituting anlotinib for bevacizumab. Grade ≥3 treatment-related adverse events were substantially more common with anlotinib (64.9% vs 44.8%). The paper's phrase 'similar antitumor activity' describes the point estimate, not a demonstrated equivalence, and the honest read is that an oral TKI failed to replace an established backbone while adding 20 points of high-grade toxicity.
Post angle: A clean, large, first-line phase 3 in mCRC that answers no — worth reading precisely because it was designed well enough for the negative to mean something. #GIOnc #CRC #PrecisionMedicine
#3
Source: American Journal of Gastroenterology (ACG practice guideline) | Authors: Mankaney G, et al.; senior author Burke CA (ACG expert panel, multi-institutional) | Published: September 1, 2026
Score: 10/20 — Base 7 (society practice guideline, scored as CLAUDE.md scores NCCN-type guideline updates) + no study-type bonus (a guideline is not a trial) + clinical impact (+3: a GRADE-methodology guideline defines the standard of care for the syndromes it covers). No colleague-engagement bonus. Verified by exact PubMed record match with article type 'Practice Guideline' — the trial-name-plus-endpoint content check does not apply to a policy document.
The American College of Gastroenterology has issued a GRADE-methodology clinical guideline covering adenomatous colorectal polyposis syndromes, focused on familial adenomatous polyposis and MUTYH-associated polyposis. It addresses risk assessment and the selection of patients for germline testing, endoscopic and surgical risk mitigation, and chemoprevention, and spans extracolonic risk — duodenal, ampullary and gastric — rather than the colorectum alone. The document updates guidance issued under the prior ACG statement and is published as Am J Gastroenterol 2026;121(9):2086–2120. Polyposis management drifts on institutional habit more than most areas of GI practice, and a citable graded document is the practical value here rather than any single new recommendation.
Post angle: New ACG GRADE guidance on FAP and MUTYH-associated polyposis — germline testing selection, endoscopic and surgical risk mitigation, chemoprevention, and the extracolonic sites that get forgotten. #GIOnc #CRC #FAP
#4
Source: Nature Cancer | Authors: Gong J, et al.; senior author Bhowmick NA (Cedars-Sinai / UCLA) | Published: August 31, 2026
Score: 9/20 — Base 8 (Nature Cancer — Nature-portfolio title added to the scoring table this run) + phase 1 single-arm (+1; below the +2 the table gives phase 2, since this is a dose-finding study) + clinical impact (+0 — the survival comparison is against historical controls, not a randomised arm, so no survival-benefit bonus is defensible). No colleague-engagement bonus.
This open-label phase 1 study added L-glutamine to gemcitabine/nab-paclitaxel in 16 treatment-naive patients with advanced pancreatic ductal adenocarcinoma, meeting the recommended phase 2 dose at maximum doses of both agents (NCT04634539). Objective response rate was 44%, including 12.5% complete responses, with tumour shrinkage observed in 94% of subjects; median PFS was 8.5 months (95% CI 6–NR) and median OS 22 months (95% CI 11–NR). Grade ≥3 treatment-related adverse events occurred in 66.7%, attributed primarily to the gemcitabine/nab-paclitaxel backbone. The authors frame the result as nearly doubling ORR and tripling OS versus historical gemcitabine/nab-paclitaxel alone — but that is a non-randomised comparison in sixteen patients with a very wide OS confidence interval, so this is a signal worth a randomised test, not a survival result. Metabolic targeting in PDAC has produced striking early numbers before that did not survive randomisation.
Post angle: ORR 44% and mOS 22 months in advanced PDAC will get attention — the number that matters is n=16, single-arm, versus historical controls. Worth a randomised trial, not a practice change. #GIOnc #PDAC #PancreaticCancer
#5
Source: ESMO Gastrointestinal Oncology | Authors: Jinnaah SM, Owens L, Cabalag C, Lee MM, Liu DS (Northern Health / Austin Health / Peter MacCallum, Australia) | Published: August 17, 2026
Score: 9/20 — Base 5 (ESMO Gastrointestinal Oncology — a young society title not in the scoring table, left at Other rather than inheriting a tier from the ESMO name) + meta-analysis (+2) + survival benefit (+2: significant OS and RFS benefit in the partial-responder stratum). No colleague-engagement bonus. Ranked above the biliary phase 2 despite the modest base score because the evidence base is 6600 patients and the question is one clinicians face at every post-resection visit.
This PRISMA-conducted systematic review and meta-analysis asked which patients with resected esophago-gastric adenocarcinoma actually benefit from adjuvant chemotherapy after neoadjuvant treatment, stratifying by pathological response to the same regimen. Eleven studies totalling 6600 patients were reviewed and five totalling 4688 were meta-analysed, with patients trichotomised into minimal, partial and complete pathological responders. Partial responders derived a clear benefit — RFS HR 0.71 (95% CI 0.57–0.87) and OS HR 0.64 (95% CI 0.53–0.77). Complete responders did not (RFS HR 0.57, 95% CI 0.19–1.73; OS HR 1.00, 95% CI 0.32–3.08), nor did minimal responders (OS HR 0.72, 95% CI 0.49–1.05), though both strata are small and their confidence intervals wide. The clinically useful reading is that the patients who half-respond are the ones who need the rest of the course, while complete responders are the obvious de-escalation candidates — a hypothesis this analysis supports but cannot settle.
Post angle: Pathological response after neoadjuvant chemo may tell you who still needs adjuvant treatment: partial responders benefit (OS HR 0.64), complete responders show none. #GIOnc #GastricCancer #EsophagealCancer
Additional Papers of Interest
-
Translational Oncology (EORTC) — single-arm phase 2, n=50: 6-month PFS 61.2% (80% CI 51.7–69.5) met the primary endpoint, mPFS 8.3 mo, ORR 40.8%, mOS 13.4 mo; the PD-L1 biomarker HRs both cross 1 (PFS 0.59, OS 0.68), so the biomarker story is hypothesis-generating only
-
ESMO Gastrointestinal Oncology — systematic review and meta-analysis of 896 paired primary-metastasis samples across 11 studies: 21% discordance (95% CI 18–24), Cohen's κ 0.57, with loss at the metastatic site far more common (35.0%) than gain (14.2%); single-site primary testing may misclassify zolbetuximab eligibility
-
ESMO Gastrointestinal Oncology — pooled individual-patient analysis of 180 patients from the two GOIM rechallenge trials this digest led with on May 20: liver involvement (PFS HR 2.19) and an anti-EGFR-free interval ≤16 months (HR 1.62) predict worse outcomes with cetuximab-avelumab, while single-agent cetuximab activity was unaffected by clinical factors
-
Am J Gastroenterol — 6 studies, 1454 participants with reflux symptoms and no Barrett's history: pooled sensitivity 0.87 (95% CI 0.80–0.94), specificity 0.88 (95% CI 0.80–0.95), NPV 0.96 at 20% prevalence; the pooled companion to the BEST3 long-term follow-up this digest covered on July 15
-
Eur J Cancer (AGITG) — 135 of 574 enrolled patients were ≥70: more preoperative dose reductions, omissions and delays (CRT 55% vs 35%, p=0.004) and more grade ≥3 diarrhoea in the chemo arm (21% vs 6%, p<0.001), but resection rates, surgical complications, nodal yield and 30/90-day mortality were all comparable, and all four OS/PFS hazard-ratio CIs cross 1
-
Dig Liver Dis — 485 SiLVER patients compared on explant histopathology across Milan, UCSF, Up-to-7 and Metroticket 2.0: discrimination was modest and statistically indistinguishable between all four (OS C-index 0.55–0.57), yet Up-to-7 would classify 83.9% as eligible versus Milan's 65.6%
Back to all digests